ClinicalTrials.gg
CompletedNCT04081350Updated Feb 20, 2024

A Study of LY3471851 in Participants With Eczema

A Phase 1 interventional study of LY3471851 and Placebo in Dermatitis, Atopic, sponsored by Nektar Therapeutics. Completed at 20 sites in United States. Open to participants aged 18 Years to 70 Years. Per ClinicalTrials.gov, last updated 2024-02-20.

Sponsored by Nektar Therapeutics · Phase 1, Interventional, and Basic science

From the registry’s dates

  • Primary completion was Jun 2022, 4 years 4 months ago, and no results have been posted to the registry.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
48
Allocation
Randomized
Ages
18 Years to 70 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 639 studies in Dermatitis, Atopic with a site in United States — 78 open to participants now, 117 under way, 18 of them phase 3. Dermatitis, Atopic · United States.

Enrollment
349th of 544
48 · median 96
Started
2019
with 57 others
Phase 1
82 of 639
10 open now
Registered
343rd of 639
by date

Among the 639 studies in Dermatitis, Atopic with a site in United States, this one is the 349th largest by enrollment of the 544 interventional ones that give a count, is one of 58 that started in 2019, is one of 82 in phase 1, and was the 343rd registered.

Dermatitis, Atopic

1,594 studies on the registry are indexed under Dermatitis, Atopic; 287 are open to participants now.

Browse Dermatitis, Atopic studies →

Open to participants now

78 of the 639 studies in Dermatitis, Atopic with a site in United States are open now. Recruiting first, the newest first:

73 more — sign in →

All 78 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 194 Dermatitis, Atopic studies recruiting now, 83 (43%) set no upper age limit and 95 (49%) stop at 75 or younger; 94 take children under 18; 51 take healthy volunteers.

This study: 18 Years to 70 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 639 studies in Dermatitis, Atopic with a site in United States, or all of them as a file.
02

Study summary

The main purpose of this study is to learn more about the safety and side effects of LY3471851 when given by injection just under the skin to participants with eczema. The study will last up to 48 weeks and may include up to 23 visits to the study center.

03

Conditions studied

  • Dermatitis, Atopic

Browse trials for

04

Who can participate

Ages eligible
18 Years to 70 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Have a confirmed diagnosis of atopic dermatitis (AD) for least 12 months
  • Have active AD according to study specific criteria
  • Be willing and able to undergo skin

Exclusion criteria

Exclusion Criteria:

  • Have received certain topical medications for AD within 14 days prior to baseline
  • Have received certain systemic medications for AD within 4 weeks prior to baseline
  • Have received LY3471851 previously
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Biopsy and archival tissue

A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.

Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.

05

Study design

Phase
Phase 1
Primary purpose
Basic science
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Investigator)
Enrollment
48 participants (actual)

Study arms

  • Active comparator
    10 µg/kg LY3471851

    Participants received subcutaneous (SC) injection of 10 microgram per kilogram (μg/kg) LY3471851 every 2 weeks for a treatment period of 12 weeks.

    Drug: LY3471851

  • Active comparator
    12 µg/kg LY3471851

    Participants received subcutaneous injection of 12 μg/kg LY3471851 every 2 weeks for a treatment period of 12 weeks.

    Drug: LY3471851

  • Active comparator
    24 µg/kg LY3471851

    Participants received subcutaneous injection of 24 μg/kg LY3471851 every 2 weeks for a treatment period of 12 weeks.

    Drug: LY3471851

  • Placebo comparator
    Placebo

    Participants received subcutaneous injection of placebo every 2 weeks for a treatment period of 12 weeks.

    Drug: Placebo

Interventions

  • Administered SC

    Also known as: NKTR-358

  • DrugPlacebo

    Administered SC

06

What researchers measure

Primary outcomes

  1. Number of Participants with One or More Serious Adverse Event(s) (SAEs) Considered by the Investigator to be Related to Study Drug Administration

    A summary of SAEs and other non-serious adverse events (AEs), regardless of causality, will be reported in the Reported Adverse Events module

    Time frame: Baseline through Study Completion (up to Week 48)

Secondary outcomes

  1. Pharmacokinetics (PK): Area Under the Concentration Versus Time Curve (AUC) of LY3471851

    PK: AUC of LY3471851

    Time frame: Postdose on Day 1 through Day 14

  2. PK: Trough Concentrations (Ctrough) of LY3471851

    PK: Ctrough of LY3471851

    Time frame: Week 12

  3. PK: Maximum Concentration (Cmax) of LY3471851

    PK: Cmax of LY3471851

    Time frame: Postdose on Day 1 through Day 14

07

Study locations

20 sites
  • Arkansas Research Trials, LLC
    North Little Rock, Arkansas 72117, United States
  • California Dermatology & Clinical Research Institute
    Encinitas, California 92024, United States
  • Center For Dermatology Clinical Research, Inc.
    Fremont, California 94538, United States
  • Therapeutics Clinical Research
    San Diego, California 92123, United States
  • Clinical Science Institute
    Santa Monica, California 90404, United States
  • Miami Dermatology and Laser Research
    Miami, Florida 33173, United States
  • ForCare Clinical Research
    Tampa, Florida 33613-1244, United States
  • Medical Dermatology Specialists
    Sandy Springs, Georgia 30328, United States
  • Dawes Fretzin Clinical Research Group, LLC
    Indianapolis, Indiana 46250, United States
  • Skin Sciences
    Louisville, Kentucky 40217, United States
  • Derm Center
    Troy, Michigan 48084, United States
  • ActivMed Practices and Research
    Portsmouth, New Hampshire 03801, United States
  • Remington-Davis, Inc
    Columbus, Ohio 43215, United States
  • Unity Clinical Research
    Oklahoma City, Oklahoma 73118, United States
  • Paddington Testing Company Inc
    Philadelphia, Pennsylvania 19103, United States
  • DermDox Centers for Dermatology
    Sugarloaf, Pennsylvania 18249, United States
  • Studies in Dermatology, LLC
    Cypress, Texas 77433, United States
  • Rodgers Dermatology
    Frisco, Texas 75034, United States
  • Progressive Clinical Research
    San Antonio, Texas 78213, United States
  • Complete Dermatology
    Sugar Land, Texas 77478, United States
08

References and documents

Individual participant data

Plan to share: No

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Dec 2019 to primary completion in Jun 2022, 30 months.

Of 114 industry-sponsored phase 1 interventional studies under Dermatitis, Atopic, half reached primary completion within 12 months of starting (the median), counting those still running; a quarter within 5 and three quarters within 20. This study's 30 months is above that.

Counting every sponsor, half of 131 studies reached it within 13 months; a quarter within 5 and three quarters within 20.

How these figures are worked out, and which studies are left out of them.

Registered
Sep 5, 2019
First posted
Sep 9, 2019
StartActual
Dec 4, 2019
Primary completionActual
Jun 24, 2022
CompletionActual
Jun 24, 2022
Last update
Feb 20, 2024
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Feb 20, 2024, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT04081350
Responsible party
Sponsor
First posted
Sep 9, 2019
Start date
Dec 4, 2019
Primary completion
Jun 24, 2022
Completion
Jun 24, 2022
Last update
Feb 20, 2024

Study contacts

Study Director
study director · Nektar Therapeutics

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Feb 2024. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Rezpegaldesleukin

Start the discussion